fumidil Report issue

Biological Experimental
ChEMBL DrugBank Drug Central MeSH PubChem

Active Ingredient History

Fumagillin, an antimicrobial compound first isolated in 1949 from the fungus Aspergillus fumigatusa, naturally occurring water-insoluble antibacterial agent developed by sanofi-aventis, is approved in France for the treatment of microsporidiosis. Fumagillin (Flisint, Sanofi-Aventis, Paris, France) has been approved in France since 2002 for the treatment of intestinal microsporidiosis due to E. bieneusi in patients with AIDS, and is also available through an expanded access program for patients without AIDS. It has not been approved, however, by the US Food and Drug Administration. The discovery of fumagillin, a MetAP-2 inhibitor, with potent antiangiogenic and antiproliferative activities promoted the development of fumagillin analogues as a novel class of anticancer agents. It has been the subject of research in cancer treatments by employing its angiogenesis inhibitory properties.   NCATS

Chemistry

  • SMILES: CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]3(C)O[C@@H]3CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O
  • InChIKey: NGGMYCMLYOUNGM-CSDLUJIJSA-N
  • Mol. Mass: 458.544
  • ALogP: 3.92
  • ChEMBL Molecule:
    fumagillin  
More Chemistry

Pharmacology

Alternative names

amebacilin | flisint | fugillin | fumagillin | (-)-fumagillin | fumidil | fumidil b

Indications (1)

Approved Indications (1)


 

Microsporidiosis (approved 2001)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue